Semaglutide
Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
ESSENCE Trial: Phase 3 Design and Baseline Characteristics of Semaglutide 2.4 mg in MASH
Design and baseline-cohort paper for the phase 3 ESSENCE trial of semaglutide 2.4 mg in biopsy-proven MASH with fibrosis stage 2 or 3; no efficacy outcomes are reported. PICO summary and expert commentary.
Integrated Data Platform Plus Dietary Management for Type 2 Diabetes
A single-centre randomized trial testing an integrated data platform plus dietary management against routine care in 180 adults with type 2 diabetes. PICO summary and expert commentary.
Semaglutide and Primary Prevention of Diabetic Kidney Disease: A SUSTAIN 6 Post Hoc Analysis
A post hoc analysis of SUSTAIN 6 reports lower odds of new-onset diabetic kidney disease with semaglutide versus placebo in people with type 2 diabetes. PICO summary and expert commentary.
Semaglutide vs Sitagliptin in T2D: Baseline-Characteristic Consistency (SUSTAIN China Post Hoc)
A post hoc analysis of SUSTAIN China examining whether the glycaemic efficacy of once-weekly semaglutide versus sitagliptin in adults with type 2 diabetes varies by baseline characteristics. PICO summary and expert commentary.
Insulin Icodec plus Semaglutide (IcoSema): Single-Dose Pharmacokinetics
A small single-dose pharmacokinetic study found that combining insulin icodec and semaglutide into IcoSema roughly doubled semaglutide peak concentration without changing total exposure of either drug. PICO summary and expert commentary.
FLOW Trial: Semaglutide Kidney Benefit With and Without Background SGLT2 Inhibitors
A pre-specified FLOW subgroup analysis tests whether baseline SGLT2 inhibitor use modifies semaglutide's kidney and cardiovascular benefit in type 2 diabetes with CKD. PICO summary and expert commentary.
Oral Semaglutide and Appetite Control Trial
A small mechanistic randomized trial found once-daily oral semaglutide 50 mg cut ad libitum energy intake by 39.2 percentage points versus placebo and reduced body weight, with no change in gastric emptying. PICO summary and expert commentary.
PIONEER 12: Oral Semaglutide vs Sitagliptin in a Predominantly Chinese Type 2 Diabetes Population
PIONEER 12 was a 26-week double-blind Phase IIIa trial showing all three doses of once-daily oral semaglutide lowered HbA1c and body weight more than sitagliptin 100 mg in a predominantly Chinese type 2 diabetes population. PICO summary and expert commentary.